Table 3. Comparison between rifaximin and control groups after propensity matching.
The rifaximin and control groups were matched in a 1:1 and 39 patients in both groups were selected. The propensity matching reduced differences between the 2 groups that existed before the matching.
| Variables | Control (n=39) | Rifaximin (n=39) | P value |
|---|---|---|---|
| Recipient age (y. o) | 57 (21–72) | 59 (37–68) | 0.519 |
| Recipient gender (female / male) | 9 (23.1%) / 30 (76.9%) | 11 (28.2%) / 28 (71.8%) | 0.604 |
| Recipient race | 0.986 | ||
| White | 10 (25.6%) | 10 (25.6%) | |
| Hispanic | 21 (53.8%) | 20 (51.3%) | |
| American African | 1 (2.6%) | 2 (5.1%) | |
| Asian | 4 (10.3%) | 4 (10.3%) | |
| Others | 3 (7.7%) | 3 (7.7%) | |
| Indication of OLT | 0.106 | ||
| HBV | 4 (10.3%) | 0 | |
| HCV | 23 (59.0%) | 20 (51.3%) | |
| EtOH | 4 (10.3%) | 5 (12.8%) | |
| NASH | 3 (7.7%) | 10 (25.6%) | |
| ALF | 4 (10.3%) | 4 (10.3%) | |
| Others | 1 (2.6%) | 0 | |
| Past history of recipient | |||
| Smoking | 23 (59.0%) | 18 (46.2%) | 0.257 |
| Hypertension | 16 (41.0%) | 16 (41.0%) | >0.999 |
| Diabetes | 14 (35.9%) | 12 (30.8%) | 0.631 |
| Coronary artery disease | 4 (10.3%) | 8 (20.5%) | 0.209 |
| Concomitant HCC | 22 (56.4%) | 18 (46.2%) | 0.365 |
| Pretransplant AST (IU/L) | 50 (20–885) | 63 (20–197) | 0.285 |
| Pretransplant ALT (IU/L) | 30 (9–1170) | 31 (11–134) | 0.780 |
| MELD | 17 (6–43) | 25 (9–40) | 0.206 |
| Preoperative hospital stay (days) | 1 (0–35) | 1 (0–47) | 0.726 |
| Preoperative ICU stay | 5 (12.8%) | 4 (10.3%) | 0.723 |
| Donor age (y. o.) | 36 (8–65) | 35 (12–70) | 0.853 |
| Donor gender (female / male) | 13 (33.3%) / 26 (66.7%) | 17 (43.6%) / 22 (56.4%) | 0.352 |
| Donor race | 0.541 | ||
| White | 17 (43.6%) | 21 (53.8%) | |
| Hispanic | 14 (35.9%) | 10 (25.6%) | |
| American African | 7 (17.9%) | 8 (20.5%) | |
| Asian | 0 | 0 | |
| Others | 1 (2.6%) | 0 | |
| Donor cause of dead | 0.961 | ||
| Head trauma | 14 (35.9%) | 13 (33.3%) | |
| Cerebrovascular accident | 14 (35.9%) | 14 (35.9%) | |
| Anoxia | 11 (28.2%) | 12 (30.8%) | |
| DCD | 3 (7.7%) | 2 (5.1%) | 0.644 |
| Donor past history | |||
| Hypertension | 13 (33.3%) | 13 (33.3%) | >0.999 |
| Diabetes | 3 (7.7%) | 8 (20.5%) | 0.104 |
| Coronary artery disease | 2 (5.1%) | 2 (5.1%) | >0.999 |
| Donor AST (IU?L) | 45 (9–483) | 42 (13–294) | 0.487 |
| Donor ALT (IU/L) | 40 (7–193) | 32 (9–165) | 0.171 |
| Donor T-Bil (mg/dl) | 0.8 (0.3–4.0) | 0.8 (0.2–2.7) | 0.756 |
| Donor PT-INR | 1.23 (0.9–2.0) | 1.20 (0.9–2.8) | 0.631 |
| Donor Risk Index | 1.5 (1.0–2.3) | 1.3 (1.0–2.3) | 0.385 |
| Cold ischemia time (min) | 429 (263–842) | 463 (211–760) | 0.355 |
| Warm ischemia time (min) | 53 (25–73) | 51 (27–81) | 0.656 |